The anti-AIDS drug market is currently dominated by the Mumbai based Cipla. Presently, Ranbaxy laboratories, the country's largest pharmaceutical company, is planning to enter the anti-AIDS drugs segment. According to Ranbaxy's regional director for India and west Asia, S D Kaul, the company is in a position to launch Lamivudine, Nevirapine, Aabacavir and Indinavir products in the Indian market shortly.
Ranbaxy's subsidiary, the Hyderabad-based Vorin Laboratories which is a bulk drug manufacturer, will be formulating the drugs which will be converted to the final drug at Ranbaxy's unit at Dewas in Madhya pradesh. The company has plans for in keeping the vast opportunities for the segment offers. The anti-AIDS drug segment also witnessed the entry of many more pharmaceutical companies including GlaxoSmithKline Pharmaceuticals, Aurobindo Pharmaceuticals and Zydus Cadilla.
Recently, the US based Dade Behring diagnostic company renewed its contract with Ranbaxy, putting an end to the guesswork that the US company would convert the distribution arrangement into a financial bind. Ranbaxy has ruled out the possibility of forming a joint venture with Dade Behring for the diagnostic business, which is a part of Ranbaxy. The company's main motive is to develop this anti-viral drug rather than grab the market share.